Antitumor activity of kasugamycin in primary and metastatic lung cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210101
- Recipient
-
Brown University UEI E3FDXZ6TBHW3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $159,128
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Originally
- Place of performance
- Providence, RI 02912, USA
Award details come from USAspending.gov.
About this award
This Project Grant from the Defense Health Agency will fund $159,128 to Brown University for research on the antitumor activity of kasugamycin in primary and metastatic lung cancer. The award period is from February 15, 2022 to August 14, 2023. The funding falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research aimed at transforming military and public health care through innovative medical solutions for battlefield injuries and other health issues. Specifically, the grant will support Brown University's investigation into using kasugamycin to treat primary lung tumors and lung cancer that has metastasized to other parts of the body.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $159,128 |
Quick answers
Who received award W81XWH2210101?
W81XWH2210101 was awarded to Brown University by Defense Health Agency (Department of Defense) on February 15, 2022.
How much is award W81XWH2210101 worth?
$159,128 has been obligated on W81XWH2210101.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award